AR089957A1 - Combinaciones farmaceuticas, combinaciones sinergicas - Google Patents
Combinaciones farmaceuticas, combinaciones sinergicasInfo
- Publication number
- AR089957A1 AR089957A1 ARP130100415A ARP130100415A AR089957A1 AR 089957 A1 AR089957 A1 AR 089957A1 AR P130100415 A ARP130100415 A AR P130100415A AR P130100415 A ARP130100415 A AR P130100415A AR 089957 A1 AR089957 A1 AR 089957A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- solvated
- combinations
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Combinaciones farmacéuticas que comprenden un agonista de receptor b-3 adrenérgico y un antagonista de receptor muscarínico y métodos para su uso. Métodos de uso de las combinaciones farmacéuticas para el tratamiento de uno o más síntomas asociados a la vejiga hiperactiva, por ejemplo, frecuencia de urgencia, nocturia e incontinencia urinaria. Reivindicación 3: La combinación de acuerdo con las reivindicaciones 1 ó 2, en donde dicho agonista de receptor b-3 adrenérgico comprende un compuesto seleccionado del grupo consistente en solabegron, CL-316,243, mirabegron, sus sales farmacéuticamente aceptables, sus solvatos farmacéuticamente aceptables, sales farmacéuticamente aceptables solvatadas con sus solventes farmacéuticamente aceptables. Reivindicación 5: La combinación de acuerdo con la reivindicación 3, en donde dicho agonista de receptor b-3 adrenérgico comprende mirabegron, o una sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o una sal farmacéuticamente aceptable solvatada con un solvente farmacéuticamente aceptable de él. Reivindicación 10: Una combinación sinérgica para aliviar uno o más síntomas asociados con vejiga hiperactiva (OAB), que comprende: (i) una cantidad terapéuticamente efectiva de solabegron, o de una sal farmacéuticamente aceptable, o de un solvato farmacéuticamente aceptable, o de una sal farmacéuticamente aceptable del mismo solvatada con uno de sus solventes farmacéuticamente aceptables; e (ii) una cantidad terapéuticamente efectiva, o una cantidad subterapéuticamente efectiva, de tolterodina o de una sal farmacéuticamente aceptable, o de un solvato farmacéuticamente aceptable, o de una de sus sales farmacéuticamente aceptables solvatadas con un solvente farmacéuticamente aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261596893P | 2012-02-09 | 2012-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089957A1 true AR089957A1 (es) | 2014-10-01 |
Family
ID=48948043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130100415A AR089957A1 (es) | 2012-02-09 | 2013-02-08 | Combinaciones farmaceuticas, combinaciones sinergicas |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP2811989A1 (es) |
JP (1) | JP2015509931A (es) |
KR (1) | KR20150020160A (es) |
CN (1) | CN104684549A (es) |
AR (1) | AR089957A1 (es) |
AU (1) | AU2013216864A1 (es) |
CA (1) | CA2864173A1 (es) |
HK (1) | HK1204966A1 (es) |
IL (1) | IL234033A0 (es) |
PH (1) | PH12014501814A1 (es) |
SG (1) | SG11201404776PA (es) |
TW (1) | TW201338772A (es) |
WO (1) | WO2013119910A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
EP3226849A4 (en) | 2014-12-03 | 2018-05-09 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
FI3365321T3 (fi) | 2015-10-23 | 2024-01-02 | B3Ar Therapeutics Inc | Solabegron-Zwitterioni ja sen käyttöjä |
KR101868438B1 (ko) | 2017-04-13 | 2018-06-20 | (주) 성운파마코피아 | 아미드 유도체의 제조방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL124473C (es) | 1960-07-26 | |||
US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
TW200800953A (en) * | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
EP2141992A1 (en) * | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
WO2011025690A1 (en) | 2009-08-27 | 2011-03-03 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
MX2012004134A (es) * | 2009-10-07 | 2012-05-08 | Merck Sharp & Dohme | Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. |
-
2013
- 2013-02-08 SG SG11201404776PA patent/SG11201404776PA/en unknown
- 2013-02-08 AU AU2013216864A patent/AU2013216864A1/en not_active Abandoned
- 2013-02-08 CA CA2864173A patent/CA2864173A1/en not_active Abandoned
- 2013-02-08 EP EP13704702.3A patent/EP2811989A1/en not_active Withdrawn
- 2013-02-08 KR KR20147023969A patent/KR20150020160A/ko not_active Application Discontinuation
- 2013-02-08 AR ARP130100415A patent/AR089957A1/es unknown
- 2013-02-08 WO PCT/US2013/025285 patent/WO2013119910A1/en active Application Filing
- 2013-02-08 CN CN201380019041.9A patent/CN104684549A/zh active Pending
- 2013-02-08 TW TW102105243A patent/TW201338772A/zh unknown
- 2013-02-08 JP JP2014556709A patent/JP2015509931A/ja active Pending
-
2014
- 2014-08-10 IL IL234033A patent/IL234033A0/en unknown
- 2014-08-11 PH PH12014501814A patent/PH12014501814A1/en unknown
-
2015
- 2015-06-17 HK HK15105751.1A patent/HK1204966A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL234033A0 (en) | 2014-09-30 |
HK1204966A1 (en) | 2015-12-11 |
SG11201404776PA (en) | 2014-09-26 |
JP2015509931A (ja) | 2015-04-02 |
TW201338772A (zh) | 2013-10-01 |
CN104684549A (zh) | 2015-06-03 |
KR20150020160A (ko) | 2015-02-25 |
PH12014501814A1 (en) | 2014-11-24 |
AU2013216864A1 (en) | 2014-09-11 |
CA2864173A1 (en) | 2013-08-15 |
EP2811989A1 (en) | 2014-12-17 |
WO2013119910A1 (en) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089957A1 (es) | Combinaciones farmaceuticas, combinaciones sinergicas | |
CO6680685A2 (es) | Combinaciones de agonistas del receptor beta 3-adrenergetico y antagonistas del receptor muscarínico para tratar vejiga hiperactiva | |
BR112017017135A2 (pt) | inibidores de tgf-beta | |
UY37098A (es) | Moduladores de ror-gamma | |
DOP2012000132A (es) | Composicion farmaceutica que comprende un agonista de glp-1 y metionina | |
CL2013002650A1 (es) | Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros. | |
CU20150020A7 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
CO6351785A2 (es) | Inhibidores de cinasa map p39 | |
CR20120218A (es) | Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina | |
AR093038A1 (es) | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodos para usarlos, composicion y uso | |
CO6180437A2 (es) | Derivados de sulfonamida como agonistas adrenergicos y antagonistas muscarinicos | |
CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
ECSP088514A (es) | Método para tratar danos en las articulaciones | |
CO6290644A2 (es) | Antagonista del receptor opioide selectivo kappa. | |
CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
ES2689971T3 (es) | Uso de inhibidores de PDE7 para el tratamiento de los trastornos del movimiento | |
CO6140054A2 (es) | Compuestos de dialquilfenilo con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico | |
AR069098A1 (es) | Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c | |
DOP2018000148A (es) | Compuestos de isoindol | |
EP3463312A4 (en) | DOSING SCHEMES FOR BETA-3-ADRENOCEPTORAGONISTS AND ANTIMUS CARINICAS FOR THE TREATMENT AND PREVENTION OF SYMPTOMS OF THE LOWER URINARY PATHWAYS AND OVERACTIVE BLADDER | |
UY35677A (es) | Combinaciones que comprenden compuestos maba y corticosteroides | |
CO2017005806A2 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos | |
CL2013000599A1 (es) | Compuestos derivados de diciano-piridina, agonistas selectivos de adenosina a1, para su uso en un procedimiento para el tratamiento y/o profilaxis de glaucoma, glaucoma normotensivo, hipertension ocular y/o combinaciones de los mismos; y composicion farmaceutica que comprende a uno de dichos compuestos. | |
CL2019002808A1 (es) | Métodos para prevenir o tratar enfermedades oftálmicas. | |
AR097644A1 (es) | Composiciones farmacéuticas que contienen refametinib, uso y método de tratamiento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |